Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Kadmon Holdings Inc    KDMN

KADMON HOLDINGS INC (KDMN)
My previous session
Most popular
  Report  
Real-time Quote. Real-time Cboe BZX - 01/16 03:52:49 pm
2.445 USD   +0.62%
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
01/10/2019 01/11/2019 01/14/2019 01/15/2019 01/16/2019 Date
2.43(c) 2.44(c) 2.4(c) 2.43(c) 2.44 Last
438 115 279 997 299 948 645 553 451 878 Volume
+1.67% +0.41% -1.64% +1.25% +0.41% Change
More quotes
Financials (USD)
Sales 2018 2,41 M
EBIT 2018 -81,2 M
Net income 2018 -35,3 M
Debt 2018 -
Yield 2018 -
Sales 2019 2,79 M
EBIT 2019 -89,0 M
Net income 2019 -26,7 M
Debt 2019 -
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019
Capi. / Sales2018 113x
Capi. / Sales2019 97,3x
Capitalization 272 M
More Financials
Company
Kadmon Holdings, Inc. is an integrated biopharmaceutical company engaged in the discovery, development and commercialization of small molecules and biologics to address disease areas of various unmet medical needs. The Company is developing product candidates in a number of indications within... 
Sector
Pharmaceuticals
Calendar
03/20Earnings Release
More about the company
Surperformance© ratings of Kadmon Holdings Inc
Trading Rating : Investor Rating :
More Ratings
Latest news on KADMON HOLDINGS INC
01/04Kadmon Announces Appointment of Tasos G. Konidaris as Interim Chairman of the..
GL
2018MANAGEMENT TRACKS : Schwartz steps down as Kadmon chairman
AQ
2018KADMON : Chairman Bart M. Schwartz to Step Down from Board
AQ
2018KADMON HOLDINGS, INC. : Change in Directors or Principal Officers, Regulation FD..
AQ
2018Kadmon Chairman Bart M. Schwartz to Step Down from Board
GL
2018KADMON : Announces Updated Findings from Ongoing Phase 2 Clinical Trial of KD025..
AQ
2018KADMON HOLDINGS, INC. : Regulation FD Disclosure, Financial Statements and Exhib..
AQ
2018Kadmon Announces Updated Findings from Ongoing Phase 2 Clinical Trial of KD02..
GL
2018Kadmon Presents Data on New ROCK Inhibitor Clinical Candidate at Anti-Fibroti..
GL
2018KADMON : Provides Business Update and Reports Third Quarter 2018 Financial Resul..
AQ
More news
Sector news : Biopharmaceuticals
01:36pTEVA PHARMACEUTICAL INDUSTRIES : FDA Approves Teva's Generic Version of Epilepsy..
DJ
02:48aBAYER : Roundup Faces New Setback in France
DJ
01/15European nations weigh impact of Brexit on drug supplies
RE
01/15Drug companies greet 2019 with U.S. price hikes
RE
01/15French court cancels Monsanto weedkiller permit on safety grounds
RE
More sector news : Biopharmaceuticals
Chart KADMON HOLDINGS INC
Duration : Period :
Kadmon Holdings Inc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends KADMON HOLDINGS INC
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 4
Average target price 10,9 $
Spread / Average Target 355%
EPS Revisions
Managers
NameTitle
Harlan W. Waksal President, Chief Executive Officer & Director
Anastasios G. Konidaris Chairman
John L. Ryan Chief Medical Officer & Executive Vice President
Eugene Andrew Bauer Independent Director
Dennie Dixon Boardman Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
KADMON HOLDINGS INC16.83%272
BIOGEN12.17%66 574
CSL LIMITED6.89%63 525
ALEXION PHARMACEUTICALS14.76%24 001
BIOMARIN PHARMACEUTICAL9.40%16 586
GRIFOLS4.45%16 524